Video of dantrolene effectiveness on neuroleptic malignant syndrome associated muscular rigidity and tremor 英文参考文献.docVIP

Available online /content/11/3/415 Letter Video of dantrolene effectiveness on neuroleptic malignant syndrome associated muscular rigidity and tremor Miran Brvar1,2 and Matjaz Bunc2,3 1Poison Control Centre, University Medical Centre Ljubljana, Ljubljana, Slovenia 2Institute for Pathophysiology, Medical Faculty, Zaloska cesta 4, 1000 Ljubljana, Slovenia 3Department for Cardiology, University Medical Center Ljubljana, Zaloska cesta 7, Ljubljana, Slovenia Corresponding author: Miran Brvar, miran.brvar@kclj.si Published: 1 June 2007 Critical Care 2007, 11:415 (doi:10.1186/cc5907) This article is online at /content/11/3/415 ? 2007 BioMed Central Ltd Neuroleptic malignant syndrome (NMS) is an uncommon but 1 day there was no clinical improvement and so bromo- criptine was withdrawn. Then, 60 mg (1 mg/kg) dantrolene was administered intravenously over 5 min. Muscle rigidity, cogwheel phenomena and tremor disappeared within 10 min (video footage is available in Additional file 2), but they gradually reappeared within an hour. The dantrolene infusion potentially fatal adverse reaction to neuroleptic drugs, including amisulpride [1,2]. NMS most commonly presents with increased body temperature, muscular rigidity of a ‘lead pipe’ nature, altered mental status and autonomic dysfunction. Other extrapyramidal movement disorders such as tremor and cogwheel phenomena are also frequently present. The was repeated three times within 12 hours and body treatment of NMS includes discontinuation of contributing drugs and supportive therapy, but specific treatment with temperature gradually decreased to 37.5°C. Bromocriptine therapy was continued two more days. The patient’s level of consciousness improved and signs of NMS disappeared during subsequent days. dantrolene, bromocriptine, nondepolarizing neuromuscular paralysis and benzodiazepines, amo